Review



n acetylcysteine nac  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress n acetylcysteine nac
    N Acetylcysteine Nac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n acetylcysteine nac/product/MedChemExpress
    Average 94 stars, based on 7 article reviews
    n acetylcysteine nac - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    n acetylcysteine nac  (MedChemExpress)
    94
    MedChemExpress n acetylcysteine nac
    N Acetylcysteine Nac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n acetylcysteine nac/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    n acetylcysteine nac - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    45567 depositor resolution determination method fsc  (Thermo Fisher)
    94
    Thermo Fisher 45567 depositor resolution determination method fsc
    45567 Depositor Resolution Determination Method Fsc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/45567 depositor resolution determination method fsc/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    45567 depositor resolution determination method fsc - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    ofloxacin  (MedChemExpress)
    93
    MedChemExpress ofloxacin
    Ofloxacin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ofloxacin/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    ofloxacin - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    axial sym c6 depositor number  (Thermo Fisher)
    94
    Thermo Fisher axial sym c6 depositor number
    Axial Sym C6 Depositor Number, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/axial sym c6 depositor number/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    axial sym c6 depositor number - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    ofloxacin  (Thermo Fisher)
    94
    Thermo Fisher ofloxacin
    Ofloxacin, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ofloxacin/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    ofloxacin - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    mics deemed susceptible to ofloxacin  (Clinical and Laboratory Standards Institute)
    90
    Clinical and Laboratory Standards Institute mics deemed susceptible to ofloxacin
    Distribution of the %API for ciprofloxacin (top panel) and <t>ofloxacin</t> (bottom panel) collected in random surveys. – The dashed lines represent the tolerance limits for ciprofloxacin tablets as stated by the International Pharmacopeia (12 th Edition, 2025).
    Mics Deemed Susceptible To Ofloxacin, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mics deemed susceptible to ofloxacin/product/Clinical and Laboratory Standards Institute
    Average 90 stars, based on 1 article reviews
    mics deemed susceptible to ofloxacin - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    ofloxacin  (TargetMol)
    94
    TargetMol ofloxacin
    Distribution of the %API for ciprofloxacin (top panel) and <t>ofloxacin</t> (bottom panel) collected in random surveys. – The dashed lines represent the tolerance limits for ciprofloxacin tablets as stated by the International Pharmacopeia (12 th Edition, 2025).
    Ofloxacin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ofloxacin/product/TargetMol
    Average 94 stars, based on 1 article reviews
    ofloxacin - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    ofloxacin eye ointment  (Shenyang Xingqi Pharmaceutical Co)
    90
    Shenyang Xingqi Pharmaceutical Co ofloxacin eye ointment
    Distribution of the %API for ciprofloxacin (top panel) and <t>ofloxacin</t> (bottom panel) collected in random surveys. – The dashed lines represent the tolerance limits for ciprofloxacin tablets as stated by the International Pharmacopeia (12 th Edition, 2025).
    Ofloxacin Eye Ointment, supplied by Shenyang Xingqi Pharmaceutical Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ofloxacin eye ointment/product/Shenyang Xingqi Pharmaceutical Co
    Average 90 stars, based on 1 article reviews
    ofloxacin eye ointment - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Distribution of the %API for ciprofloxacin (top panel) and ofloxacin (bottom panel) collected in random surveys. – The dashed lines represent the tolerance limits for ciprofloxacin tablets as stated by the International Pharmacopeia (12 th Edition, 2025).

    Journal: medRxiv

    Article Title: A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: application to typhoid fever

    doi: 10.1101/2025.07.08.25331006

    Figure Lengend Snippet: Distribution of the %API for ciprofloxacin (top panel) and ofloxacin (bottom panel) collected in random surveys. – The dashed lines represent the tolerance limits for ciprofloxacin tablets as stated by the International Pharmacopeia (12 th Edition, 2025).

    Article Snippet: When exploring how different levels of resistance modified dose effects, both outcomes showed no relationship with ofloxacin dose at MICs deemed susceptible to ofloxacin (i.e., MIC ≤ 0.125 mg/L) by the Clinical and Laboratory Standards Institute (CLSI) ( and ).

    Techniques:

    Average treatment effect of different ofloxacin doses on fever clearance time (A) and failure probability (B) compared to a baseline total dose of 52 mg/kg. Effects were only estimated within the range of doses present in the data (13.8–172.4 mg/kg). All other parameters were kept at their baseline values for each individual. The grey shaded region represents a 90% credible interval. The horizontal dashed line represents no change from baseline. The vertical dashed line represents the average dose.

    Journal: medRxiv

    Article Title: A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: application to typhoid fever

    doi: 10.1101/2025.07.08.25331006

    Figure Lengend Snippet: Average treatment effect of different ofloxacin doses on fever clearance time (A) and failure probability (B) compared to a baseline total dose of 52 mg/kg. Effects were only estimated within the range of doses present in the data (13.8–172.4 mg/kg). All other parameters were kept at their baseline values for each individual. The grey shaded region represents a 90% credible interval. The horizontal dashed line represents no change from baseline. The vertical dashed line represents the average dose.

    Article Snippet: When exploring how different levels of resistance modified dose effects, both outcomes showed no relationship with ofloxacin dose at MICs deemed susceptible to ofloxacin (i.e., MIC ≤ 0.125 mg/L) by the Clinical and Laboratory Standards Institute (CLSI) ( and ).

    Techniques:

    Average treatment effect of different doses of ofloxacin at different MICs (panels) on fever clearance time compared to the average total dose of 52 mg/kg (vertical dashed line). Effects are only shown within the range of doses present in the data (13.8–172.4 mg/kg). All other parameters were kept at their baseline values for each individual. The grey shaded region represents a 90% credible interval. The horizontal dashed line represents no change compared to the average dose.

    Journal: medRxiv

    Article Title: A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: application to typhoid fever

    doi: 10.1101/2025.07.08.25331006

    Figure Lengend Snippet: Average treatment effect of different doses of ofloxacin at different MICs (panels) on fever clearance time compared to the average total dose of 52 mg/kg (vertical dashed line). Effects are only shown within the range of doses present in the data (13.8–172.4 mg/kg). All other parameters were kept at their baseline values for each individual. The grey shaded region represents a 90% credible interval. The horizontal dashed line represents no change compared to the average dose.

    Article Snippet: When exploring how different levels of resistance modified dose effects, both outcomes showed no relationship with ofloxacin dose at MICs deemed susceptible to ofloxacin (i.e., MIC ≤ 0.125 mg/L) by the Clinical and Laboratory Standards Institute (CLSI) ( and ).

    Techniques:

    Average treatment effect of different doses of ofloxacin at different MICs (panels) on failure probability compared to the average total dose of 52 mg/kg (vertical dashed line). Effects are only shown within the range of doses present in the data (13.8–172.4 mg/kg). All other parameters were kept at their baseline values for each individual. The grey shaded region represents a 90% credible interval. The horizontal dashed line represents no change compared to the average dose.

    Journal: medRxiv

    Article Title: A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: application to typhoid fever

    doi: 10.1101/2025.07.08.25331006

    Figure Lengend Snippet: Average treatment effect of different doses of ofloxacin at different MICs (panels) on failure probability compared to the average total dose of 52 mg/kg (vertical dashed line). Effects are only shown within the range of doses present in the data (13.8–172.4 mg/kg). All other parameters were kept at their baseline values for each individual. The grey shaded region represents a 90% credible interval. The horizontal dashed line represents no change compared to the average dose.

    Article Snippet: When exploring how different levels of resistance modified dose effects, both outcomes showed no relationship with ofloxacin dose at MICs deemed susceptible to ofloxacin (i.e., MIC ≤ 0.125 mg/L) by the Clinical and Laboratory Standards Institute (CLSI) ( and ).

    Techniques:

    Expected change in fever clearance time when patients take ofloxacin with %API distributed according to the ofloxacin distribution shown in compared to when they take ofloxacin with 100% API. Negative values indicate that the distribution decreased (i.e., improved) the fever clearance time. The shaded region shows 90% credible intervals. The panels show different target doses (i.e., the dose represented by 100% API). The vertical dashed line indicates the breakpoint for ofloxacin; MICs to the right of this line are considered non-susceptible.

    Journal: medRxiv

    Article Title: A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: application to typhoid fever

    doi: 10.1101/2025.07.08.25331006

    Figure Lengend Snippet: Expected change in fever clearance time when patients take ofloxacin with %API distributed according to the ofloxacin distribution shown in compared to when they take ofloxacin with 100% API. Negative values indicate that the distribution decreased (i.e., improved) the fever clearance time. The shaded region shows 90% credible intervals. The panels show different target doses (i.e., the dose represented by 100% API). The vertical dashed line indicates the breakpoint for ofloxacin; MICs to the right of this line are considered non-susceptible.

    Article Snippet: When exploring how different levels of resistance modified dose effects, both outcomes showed no relationship with ofloxacin dose at MICs deemed susceptible to ofloxacin (i.e., MIC ≤ 0.125 mg/L) by the Clinical and Laboratory Standards Institute (CLSI) ( and ).

    Techniques:

    Expected change in fever clearance time when patients take ofloxacin with %API distributed according to the ciprofloxacin distribution shown in compared to when they take ofloxacin with 100% API. Negative values indicate that the distribution decreased (i.e., improved) the fever clearance time. The shaded region shows 90% credible intervals. The panels show different target doses (i.e., the dose represented by 100% API). The vertical dashed line indicates the breakpoint for ofloxacin; MICs to the right of this line are considered non-susceptible.

    Journal: medRxiv

    Article Title: A novel framework for quantifying the clinical impact of substandard and falsified antimicrobials: application to typhoid fever

    doi: 10.1101/2025.07.08.25331006

    Figure Lengend Snippet: Expected change in fever clearance time when patients take ofloxacin with %API distributed according to the ciprofloxacin distribution shown in compared to when they take ofloxacin with 100% API. Negative values indicate that the distribution decreased (i.e., improved) the fever clearance time. The shaded region shows 90% credible intervals. The panels show different target doses (i.e., the dose represented by 100% API). The vertical dashed line indicates the breakpoint for ofloxacin; MICs to the right of this line are considered non-susceptible.

    Article Snippet: When exploring how different levels of resistance modified dose effects, both outcomes showed no relationship with ofloxacin dose at MICs deemed susceptible to ofloxacin (i.e., MIC ≤ 0.125 mg/L) by the Clinical and Laboratory Standards Institute (CLSI) ( and ).

    Techniques: